Pramiracetam (PRC)

Pramiracetam is a nootropic drug derived from piracetam, and is more potent. It belongs to the racetam family of nootropics. Pramiracetam is used off-label for a wide range of applications. Pramiracetam, like other members of the racetam family, is generally well tolerated by humans. In a study where a small sample of human subjects with varying degrees of Alzheimer"""s disease were treated for 5–8 weeks, symptoms were few and mild. At relatively low dosages, a few participants reported headaches. One participant at the highest end of the dosage spectrum experienced sleepiness, decreased appetite, and dizziness. In another study where a small sample of healthy, male human subjects were treated for 10 days, no adverse events were reported. Pramiracetam was developed by Parke-Davis in the late 1970s. The first patents for this drug appeared in 1978 (Belgium) and 1979 (US), concurrent with its first reporting of nootropic.